• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Zymeworks Inc.

    11/10/25 4:26:39 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYME alert in real time by email
    DEFA14A 1 d86043ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    ZYMEWORKS INC.

    (Name of Registrant as Specified in its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO

    OnlineGo to https://www.envisionreports.com/ZYME or scan the QR code login details are located in the shaded bar below.Votes must be received by the closing of polls at the meeting for shares held directly and by 11:59 p.m. ET on December 25, 2025 for shares held via Shareworks.Stockholder Meeting NoticeImportant Notice Regarding the Availability of Proxy Materials for the Zymeworks Inc. Stockholder Meeting to be Held on December 30, 2025Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice, Proxy Statement and the Annual Report on Form 10-K are available at: https://www.envisionreports.com/ZYMEEasy Online Access View your proxy materials and vote.Step1:Go to https://www.envisionreports.com/ZYME.Step2:Click on the icon on the right to view meeting materials.Step3:Return to the envisionreports.com window and follow the instructions on the screen to log in.Step4:Make your selections as instructed on each screen for your delivery preferences.Step5:Vote your shares.When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.Obtaining a Copy of the Proxy Materials If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before December 20, 2025 to facilitate timely delivery. 2 NOTCOY046UICOnlineGo to https://www.envisionreports.com/ZYME or scan the QR code login details are located in the shaded bar below.Votes must be received by the closing of polls at the meeting for shares held directly and by 11:59 p.m. ET on December 25, 2025 for shares held via Shareworks.Stockholder Meeting NoticeImportant Notice Regarding the Availability of Proxy Materials for the Zymeworks Inc. Stockholder Meeting to be Held on December 30, 2025Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice, Proxy Statement and the Annual Report on Form 10-K are available at: https://www.envisionreports.com/ZYMEEasy Online Access View your proxy materials and vote.Step1:Go to https://www.envisionreports.com/ZYME.Step2:Click on the icon on the right to view meeting materials.Step3:Return to the envisionreports.com window and follow the instructions on the screen to log in.Step4:Make your selections as instructed on each screen for your delivery preferences.Step5:Vote your shares.When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.Obtaining a Copy of the Proxy Materials If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before December 20, 2025 to facilitate timely delivery. 2 NOT046UIC


    LOGO

    Stockholder Meeting Notice Zymeworks Inc.s Annual Meeting of Stockholders will be held on December 30, 2025, at 9:00 a.m. Pacific Time, virtually via the Internet at meetnow.global/MZKC5MK. Proposals to be voted on at the meeting are listed below along with the Board of Directors recommendations. The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2-3:1.Election of Directors:1- Carlos Campoy2- Alessandra Cesano3- Robert E. Landry 2.Advisory vote on the compensation of our named executive officers 3.Ratification of the appointment of KPMG LLP, chartered professional accountants, as auditors for the year ending December 31, 2025 PLEASE NOTE YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.Heres how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below.If you request an email copy, you will receive an email with a link to the current meeting materials.PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials."Internet Go to https://www.envisionreports.com/ZYME."Phone Call us free of charge at 1-866-641-4276."Email Send an email to [email protected] with Proxy Materials Zymeworks Inc. in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.To facilitate timely delivery, requests for a paper copy of proxy materials must be received by December 20, 2025.


    LOGO

    C1234567890 XXXMr A Sample Designation (if any) Add1 Add2 add3 add4 add5 add6Notice of Internet Availability of Proxy Materials1234 5678 9012 345Important Notice Regarding the Availability of Proxy Materials for Zymeworks Inc. (the Company)Annual Meeting to be Held on December 30, 2025, at 9:00 a.m. Pacific Time, virtually via the Internet at meetnow.global/MZKC5MK. The U.S. securities regulators have adopted policies that permit the use of notice-and-access for proxy solicitation instead of the traditional physical delivery of proxy materials. The Company is availing itself of the notice-and-access policies and as a result, you will not be receiving a paper copy of the proxy materials in respect of the Annual Meeting unless specifically requested in accordance with the instructions in this Notice.You are receiving this notice to advise that the proxy materials for the above noted meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the meeting are on the reverse side. Your vote is important!THIS IS NOT A FORM FOR VOTINGThis communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy materials, including the Notice and Proxy Statement and Annual Report on Form 10-K are available at:https://www.envisionreports.com/ZYMEEasy Online Access A Convenient Way to View Proxy Materials and VoteWhen you go online to view materials, you can also vote your shares.Obtaining a Copy of the Proxy Materials If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before December 20, 2025 to facilitate timely delivery.ZYMQ024M7BCPUQC01.E.INT/000001/i1234


    LOGO

    Shareholder Meeting NoticeThe Companys Annual Meeting of Shareholders will be held on December 30, 2025, at 9:00 a.m. Pacific Time, virtually via the Internet at meetnow.global/MZKC5MK To attend the Annual Meeting and exercise the voting rights directly, you must (1) request a proxy from Computershare Trust Company of Canada at the address below and (2) not have previously submitted voting instructions or have submitted a written revocation of any such previous instructions. VOTING ITEMSThe Board of Directors recommends you vote FOR the following:1.Election of Directors:Nominees01. Carlos Campoy02. Alessandra Cesano03. Robert E. Landry2.Advisory vote on the compensation of our named executive officers3.Ratification of the appointment of KPMG LLP, chartered professional accountants, as auditors for the year ending December 31, 2025We encourage you to access and review all of the important information contained in the proxy materials before voting.PLEASE NOTE YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must either vote online or request a paper or email copy of the proxy materials and a voting instruction card.To assure your representation at the Annual Meeting, please complete, sign, date and return the voting instruction card that is delivered to you.Shareholders who do not wish to attend the Annual Meeting or do not wish to vote in person can vote by voting instruction card. A registered shareholder must return the completed voting instruction card to the Company:(a)by delivering the voting instruction card as instructed therein, which voting instruction card must be received by 2:00 pm Eastern Time, December 24, 2025(b)by internet at www.investorvote.com not later than December 24, 2025 at 2:00 pm Eastern Time or(c)by telephone by calling toll-free in North America at 1-866-732-8683 and following the instructions no later than December 24, 2025 at 2:00 pm Eastern Time.If you are a non-registered shareholder (i.e. you own your shares through an intermediary such as a bank, trust company or broker), you can vote your shares by following the instructions provided by your intermediary.How to Obtain Paper or Email Copies of the Proxy MaterialsShareholders may request to receive paper or email copies of current and future meeting materials by mail or email at no cost. Requests for copies may be made using your Control Number located in the shaded bar on the reverse side of this notice. If you request an email copy, you will receive an email with a hyperlink to the proxy materials. Registered shareholders may enroll to receive future meeting materials by email by visiting www.computershare.com/eDelivery and clicking on eDelivery Signup.To attend the Annual Meeting in person and exercise voting rights directly, please contact Computershare Trust Company of Canada at the following address: 3rd Floor, 510 Burrard Street Vancouver BC, V6C 3B9, or call/email [email protected]/236 982 4155.Request a paper copy of the proxy materials:BY TELEPHONE: Call Toll Free, within North America at 1-866-641-4276. BY INTERNET: Visit www.investorvote.com/ZYMEBY EMAIL: Send a request to [email protected] with Proxy Materials in the subject line.024M8B

    Get the next $ZYME alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYME

    DatePrice TargetRatingAnalyst
    10/24/2025$15.00Equal Weight
    Wells Fargo
    10/14/2025$26.00Neutral → Buy
    H.C. Wainwright
    10/10/2025$30.00Buy
    B. Riley Securities
    5/20/2025Buy
    TD Cowen
    12/16/2024$18.00Neutral → Overweight
    Analyst
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    11/1/2024$12.00Overweight → Equal Weight
    Wells Fargo
    3/21/2023$12.00Overweight
    Wells Fargo
    More analyst ratings

    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ciongoli Gregory Austin was granted 415,000 shares, increasing direct ownership by 565% to 488,500 units (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    8/12/25 8:30:06 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Landry Robert E

    4 - Zymeworks Inc. (0001937653) (Issuer)

    8/12/25 8:30:04 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Landry Robert E claimed no ownership of stock in the company (SEC Form 3)

    3 - Zymeworks Inc. (0001937653) (Issuer)

    8/12/25 8:00:09 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    SEC Filings

    View All

    SEC Form DEFA14A filed by Zymeworks Inc.

    DEFA14A - Zymeworks Inc. (0001937653) (Filer)

    11/10/25 4:26:39 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Zymeworks Inc.

    DEF 14A - Zymeworks Inc. (0001937653) (Filer)

    11/10/25 4:24:13 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Zymeworks Inc.

    10-Q - Zymeworks Inc. (0001937653) (Filer)

    11/6/25 4:16:03 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    Encouraging Phase 1 data on ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-⍺ (FR⍺), presented at the AACR-NCI-EORTC ConferenceFirst patient dosed in Phase 1 clinical trial of ZW251 for the treatment of hepatocellular carcinomaAchievement of $25.0 million development milestone from Johnson & Johnson Innovative MedicineEarned royalties of $1.0 million based on Ziihera® net product sales by Jazz and BeOne Medicines for 3Q-2025Completed share repurchases of $22.7 million under share repurchase program as of November 4, 2025Cash resources of $299.4 million as of September 30, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated

    11/6/25 4:05:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Announces Participation in Upcoming Investor Conferences

    VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: Stifel Healthcare Conference: Zymeworks' management will participate in one-on-one meetings on November 11, 2025, in New York, NY.Jefferies London Healthcare Conference: Zymeworks' management will participate in one-on-one meetings on November 17- 19, 2025, in London, UK. A

    10/28/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

    Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall response rate in gynecological cancers at doses ≥6.4mg/kgResponses observed at all doses evaluated at 3.2mg/kg and above demonstrating wide therapeutic index of Zymeworks' novel antibody-drug conjugate platformDose optimization of ZW191 in ovarian cancer to initiate in 4Q-2025Investor and analyst call to be held today at 3:30 pm Eastern Time (ET) VANCOUVER, British Columbia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company

    10/23/25 12:30:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    5/19/25 6:35:05 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/18/25 3:17:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/7/25 6:34:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Leadership Updates

    Live Leadership Updates

    View All

    Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

    VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer. In this role, Dr. Schayowitz will report directly to Zymeworks' Chair & Chief Executive Officer, Kenneth Galbraith, and work closely with the Zymeworks R&D and Business Development teams to advance the Company's broad portfolio of nominated product candidates, while also

    10/9/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

    VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointments of Greg Ciongoli and Robert E. Landry to the Company's Board of Directors, effective August 10, 2025. Mr. Ciongoli and Mr. Landry were also appointed as members of the audit committee of the Board of Directors. "Greg and Bob bring extensive financial and strategic leadership expertise that will be invaluable to Zymeworks, as we continu

    8/11/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

    VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,

    4/21/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo resumed coverage on Zymeworks with a new price target

    Wells Fargo resumed coverage of Zymeworks with a rating of Equal Weight and set a new price target of $15.00

    10/24/25 9:02:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Zymeworks from Neutral to Buy and set a new price target of $26.00

    10/14/25 8:39:20 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Zymeworks with a new price target

    B. Riley Securities initiated coverage of Zymeworks with a rating of Buy and set a new price target of $30.00

    10/10/25 8:40:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Financials

    Live finance-specific insights

    View All

    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

    VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its third quarter 2025 financial results after market close on November 6, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 6, 2025 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and w

    10/16/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with first-in-human studies planned to initiate in 2025China and European approval for zanidatamab in 2L HER2-positive biliary tract cancer (BTC) expands international patient access$48.7 million in revenue for 2Q-2025 from continued progress on existing partnerships Ziihera® net product sales by Jazz were $5.5 million for 2Q-2025Cash resources of $333.4 million as of June 30, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027Will host conference ca

    8/7/25 4:05:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

    VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its second quarter 2025 financial results after market close on August 7, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 7, 2025 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webca

    7/17/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 4:27:20 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zymeworks Inc.

    SC 13G - Zymeworks Inc. (0001937653) (Subject)

    11/13/24 4:30:24 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care